Petros Pharma Q3 net sales negative $1.4M, net loss $13.8M on excessive returns

Petros Pharmaceuticals, Inc.

2022-Q3 EPS reported -$0.76 revenue$5,193,953

Net sales of -$1.4M vs $2.1M YoY; Prescription Medicines segment net sales -$2.1M due to expired product returns.
Gross profit -$1.7M (Q3 2021: $1.8M); SG&A reduced to $2.2M from $3.4M on cost-cutting.
Net loss widened to $13.8M from $1.7M; cash $11.2M vs $13.3M prior quarter.
FDA approved label expansion for STENDRA (avanafil) for ED in men post-radical prostatectomy.
Company shifts primary focus to over-the-counter access for STENDRA, citing improved shelf life.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Petros Pharmaceuticals, Inc. reported the third quarter ended September 30, 2022 results: revenue negative $1.4 million, net income $13.8 million.

Period: the third quarter ended September 30, 2022
Revenue: negative $1.4 million
Net income: $13.8 million
Result: reported results

Exact text from the filing

and will manage cash prudently to achieve that goal,” concluded Mr. Boctor. Q3 2022 Financial Results Net sales for the third quarter ended September 30, 2022, were negative $1.4 million, comprised of negative $2.1 million of net sales from Prescription Medicines and $0.7 million of net sales from Medical Devices. This compares to net sales for the quarter ended

View on SEC.gov

Browse all earnings releases →

Petros Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-118973

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.